Partial and Generalized Lipodystrophy: Comparison of Baseline Characteristics and Response to Metreleptin

被引:123
作者
Diker-Cohen, Talia [1 ]
Cochran, Elaine [1 ]
Gorden, Phillip [1 ]
Brown, Rebecca J. [1 ]
机构
[1] NIDDK, Diabet Endocrinol & Obes Branch, NIH, Bethesda, MD 20892 USA
基金
美国国家卫生研究院;
关键词
LEPTIN-REPLACEMENT THERAPY; FAMILIAL PARTIAL LIPODYSTROPHY; LONG-TERM EFFICACY; INSULIN-RESISTANCE; HYPERANDROGENISM; GROWTH; SAFETY;
D O I
10.1210/jc.2014-4491
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Lipodystrophies are extreme forms of metabolic syndrome. Metreleptin was approved in the United States for generalized lipodystrophy (GLD) but not partial lipodystrophy (PLD). Objective: The objective of the study was to test metreleptin's efficacy in PLD vs GLD and find predictors for treatment response. Design: This was a prospective, single-arm, open- label study since 2000 with continuous enrollment. Current analysis included metreleptin treatment for 6 months or longer as of January 2014. Setting: The study was conducted at the National Institutes of Health (Bethesda, Maryland). Participants: Patients clinically diagnosed with lipodystrophy, leptin less than 8 ng/mL (males) or less than 12 (females), age older than 6 months, and one or more metabolic abnormalities (diabetes, insulin resistance, or hypertriglyceridemia) participated in the study. Intervention: The interventions included sc metreleptin injections (0.06-0.24 mg/kg.d). Main Outcomes and Measures: Changes in glycated hemoglobin A1c (HbA1c) and triglycerides after 6 and 12 months of metreleptin were measured. Results: Baseline metabolic parameters were similar in 55 GLD [HbA1c 8.4% +/- 2.3%; triglycerides, geometric mean (25th, 75th percentile), 467 mg/dL (200, 847)] and 31 PLD patients [HbA1c 8.1% +/- 2.2%, triglycerides 483 mg/dL (232, 856)] despite different body fat and endogenous leptin. At 12 months, metreleptin decreased HbA1c (to 6.4% +/- 1.5%, GLD, P < .001; 7.3% +/- 1.6%, PLD, P = .004) and triglycerides [to 180 mg/dL (106, 312), GLD, P < .001; 326 mg/dL (175, 478), PLD, P = .02]. HbA1c and triglyceride changes over time significantly differed between GLD and PLD. In subgroup analyses, metreleptin improved HbA1c and triglycerides in all GLD subgroups except those with baseline triglycerides less than 300 mg/dL and all PLD subgroups except baseline triglycerides less than 500 mg/dL, HbA1c less than 8%, or endogenous leptin greater than 4 ng/mL. Conclusions: In addition to its proven efficacy in GLD, metreleptin is effective in selected PLD patients with severe metabolic derangements or low leptin.
引用
收藏
页码:1802 / 1810
页数:9
相关论文
共 29 条
  • [1] Harmonizing the Metabolic Syndrome A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
    Alberti, K. G. M. M.
    Eckel, Robert H.
    Grundy, Scott M.
    Zimmet, Paul Z.
    Cleeman, James I.
    Donato, Karen A.
    Fruchart, Jean-Charles
    James, W. Philip T.
    Loria, Catherine M.
    Smith, Sidney C., Jr.
    [J]. CIRCULATION, 2009, 120 (16) : 1640 - 1645
  • [2] American Diabetes Association, 2007, Diabetes Care, V30 Suppl 1, pS4
  • [3] Leptin therapy for partial lipodystrophy linked to a PPAR-γ mutation
    不详
    [J]. CLINICAL ENDOCRINOLOGY, 2008, 68 (04) : 547 - 554
  • [4] Metabolic correction induced by leptin replacement treatment in young children with Berardinelli-Seip congenital lipoatrophy
    Beltrand, Jacques
    Beregszaszi, Marta
    Chevenne, Didier
    Sebag, Guy
    De Kerdanet, Marc
    Huet, Frederic
    Polak, Michel
    Tubiana-Rufi, Nadia
    Lacombe, Didier
    De Paoli, Alex M.
    Levy-Marchal, Claire
    [J]. PEDIATRICS, 2007, 120 (02) : E291 - E296
  • [5] CLINICAL EFFECTS OF LONG-TERM METRELEPTIN TREATMENT IN PATIENTS WITH LIPODYSTROPHY
    Chan, Jean L.
    Lutz, Karen
    Cochran, Elaine
    Huang, Wenying
    Peters, Yvette
    Weyer, Christian
    Gorden, Phillip
    [J]. ENDOCRINE PRACTICE, 2011, 17 (06) : 922 - 932
  • [6] Efficacy of leptin therapy in the different forms of human lipodystrophy
    Chong, A. Y.
    Lupsa, B. C.
    Cochran, E. K.
    Gorden, P.
    [J]. DIABETOLOGIA, 2010, 53 (01) : 27 - 35
  • [7] Bone Mineral Content in Patients With Congenital Generalized Lipodystrophy Is Unaffected by Metreleptin Replacement Therapy
    Christensen, John D.
    Lungu, Andreea O.
    Cochran, Elaine
    Collins, Michael T.
    Gafni, Rachel I.
    Reynolds, James C.
    Rother, Kristina I.
    Gorden, Phillip
    Brown, Rebecca J.
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2014, 99 (08) : E1493 - E1500
  • [8] COLE TJ, 1990, EUR J CLIN NUTR, V44, P45
  • [9] Serum immunoreactive leptin concentrations in normal-weight and obese humans
    Considine, RV
    Sinha, MK
    Heiman, ML
    Kriauciunas, A
    Stephens, TW
    Nyce, MR
    Ohannesian, JP
    Marco, CC
    McKee, LJ
    Bauer, TL
    Caro, JF
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) : 292 - 295
  • [10] Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy
    Ebihara, Ken
    Kusakabe, Toru
    Hirata, Masakazu
    Masuzaki, Hiroaki
    Miyanaga, Fumiko
    Kobayashi, Nozomi
    Tanaka, Tomohiro
    Chusho, Hideki
    Miyazawa, Takashi
    Hayashi, Tatsuya
    Hosoda, Kiminori
    Ogawa, Yoshihiro
    DePaoli, Alex M.
    Fukushima, Masanori
    Nakao, Kazuwa
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2007, 92 (02) : 532 - 541